The mechanism of carvedilol in experimental viral myocarditis

Current Pharmaceutical Design

Volumn 18, Issue 12, 2012, Pages 1620-1624

  Li, Yu Echun ^a   Ge, Li Sha ^a   Guan, Xue Qiang ^a   Lin, Jia Feng ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Antioxidants; Carvedilol; Cytokines; Hemodynamics; Viral myocarditis

Indexed keywords

CARVEDILOL; CYTOKINE; MATRIX METALLOPROTEINASE; METOPROLOL; PROPRANOLOL;

ANTIOXIDANT ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS MYOCARDITIS;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARBAZOLES; DISEASE MODELS, ANIMAL; MICE; MYOCARDITIS; PROPANOLAMINES;

EID: 84860177467     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799958530     Document Type: Review

References (70)

1. Baughman KL. Diagnosis of myocarditis. Death of Dallas criteria. Circulation 2006; 113: 593-95.
2. Gupta S, Markham DW, Drazner MH, Mammen PP. Fulminant myocarditis. Nat Clin Pract Cardiovasc Med 2008; 5: 693-706.
3. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000; 343: 1388-98.
4. Pauschinger M, Doerner A, Kuehl U, et al. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 1999; 99: 889-95.
5. Kuhl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 2005; 111: 887-93.
6. Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006; 114: 1581-90.
7. Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW. Myocarditis and heart failure associated with hepatitis C virus infection. J Card Fail 2006; 12: 293-8.
8. Seong IW, Choe SC, Jeon ES. Fulminant coxsackieviral myocarditis. N Engl J Med 2001; 345: 79.
9. Henke A, Zell R, Martin U, Stelzner A. Direct interferon-y-mediated protection caused by a recombinant coxsackievirus B3. Virology 2003; 315: 335-44.
10. Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008; 118: 639-48.
11. Chimenti C, Russo A, Pieroni M, et al. Intramyocyte detection of Epstein-Barr virus genome by laser capture microdissection in patients with inflammatory cardiomyopathy. Circulation 2004; 110: 3534-9.
12. Matsumori A. Hepatitis C virus induces cardiomyopathies. Circ Res. 2005; 96: 144-7.
13. Chow LH, Beisel KW, McManus BM. Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Lab Invest 1992; 66: 24-31.
14. Shi Y, Chen C, Lisewski U, et al. Cardiac deletion of the Coxsackievirus-adenovirus receptor abolishes Coxsackievirus B3 infection and prevents myocarditis in vivo. J Am Coll Cardiol 2009; 53: 1219-26.
15. Yajima T, Knowlton K. Viral Myocarditis: From the Perspective of the Virus. Circulation 2009; 119: 2615-24.
16. Huber SA. Autoimmunity in coxsackievirus B3 induced myocarditis. Autoimmunity 2006; 39: 55-61.
17. Huang CH, Vallejo JG, Kollias G, Mann DL. Role of the innate immune system in acute viral myocarditis. Basic Res Cardiol 2009;104: 228-37.
18. Shioi T, Matsumori A, Nishio R, Ono K, Kakio T, Sasayama S. Protective role of interleukin-12 in viral myocarditis. J Mol Cell Cardiol 1997; 29: 2327-34.
19. Tanaka T, Kanda T, McManus BM, et al. Overexpression of inter-leukin-6 aggravates viral myocarditis: impaired increase in tumor necrosis factor-a. J Mol Cell Cardiol 2001; 33: 1627-35.
20. Shioi T, Matsumori A, Sasayama S. Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation 1996; 94: 2930-7.
21. Lommi J, Pulkki K, Koskinen P, et al. Haemodynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure. Eur Heart J 1997; 18: 1620-5.
22. Panina-Bordignon P, Mazzeo D, Lucia PD, et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin-12. J Clin Invest 1997; 100: 1513-9.
23. Andrade-Mena CE. Inhibition of gamma interferon synthesis by catecholamines. J Neuroimmunol 1997; 76: 10-14.
24. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits tumor necrosis factor-a and potentiates inter-leukin-10 production during human endotoxemia. J Clin Invest 1996; 97: 713-9.
25. Hiraoka Y, Kishimoto C, Takada H, et al. Role of oxygen derived free radicals in the pathogenesis of coxsackievirus B3 myocarditis in mice. Cardiovasc Res 1993; 27: 957-61.
26. Hiraoka Y, Kishimoto C, Takada H, Suzaki N, Shiraki K. Effects of granulocyte colony-stimulating factor upon coxsackievirus B3 myocarditis in mice. Eur Heart J 1995; 16: 1900-6.
27. Singh N, Dhalla AK, Seneviratne C, Singal PK. Oxidative stress and heart failure. Mol Cell Biochem 1995; 147: 77-81.
28. Kaneko M, Masuda H, Suzuki H, Matsumoto Y, Kobayashi A, Yamazaki N. Modification of contractile proteins by oxygen free radicals in rat hearts. Mol Cell Biochem 1993; 125: 163-9.
29. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 1352-6.
30. Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J 1991; 65: 245-8.
31. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993; 14: 1493-8.
32. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure, US Carvediol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55.
33. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-90.
34. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126: 955-9.
35. The GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-36.
36. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-235.
37. Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-306.
38. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999; 99: 2645-51.
39. Frishman WH. Carvedilol. N Engl J Med 1998; 339: 1759-65.
40. Tominaga M, Matsumori A, Okada I, Yamada T, Kawai C. β-Blocker treatment of dilated cardiomyopathy: beneficial effect of carteolol in mice. Circulation 1991; 83: 2021-8.
41. Wang JF, Meissner A, Malek S, et al. Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis. Am J Physiol Heart Circ Physiol 2005; 289: H1577-83.
42. Rezkalla S, Kloner RA, Khatib G, Smith FE, Khatib R. Effect of metoprolol in acute coxsackievirus B3 murine myocarditis. J Am Coll Cardiol 1988; 12: 412-4.
43. Nishio R, Shioi T, Sasayama S, Matsumori A. Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J Am Coll Cardilol 2003; 41: 340-5.
44. Tschöpe C, Westermann D, Steendijk P, et al. Hemodynamic characterization of left ventricular function in experimental coxsackie-viral myocarditis: effect of carvedilol and metoprolol. EUR J Pharmacol 2004; 491: 173-9.
45. Pauschinger M, Rutschow S, Chandrasekharan K, et al. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial in-terleukin-1beta and MMP-8 expression and a modulated immune response. Eur J Heart Fail 2005; 7: 444-52.
46. Yue-chun L, Li-sha G, Jiang-hua R, et al. Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. J Cardiovasc Pharmacol 2008; 51: 92-8.
47. Yue-chun L, Li-sha G, Peng-Lin Y, et al. Carvedilol decreases elevated oxidative stress in murine coxsackievirus-induced acute viral myocarditis. Eur J Pharmacol 2010; 640: 112-6.
48. Dulin B, Abraham WT. Pharmacology of carvedilol. Am J Cardiol 2004; 93 (suppl): 3-6.
49. Kishimoto C, Takamatsu N, Kawamata H, Shinohara H, Ochiai H. Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change. J Am Coll Cardiol. 2000; 36: 1979-84.
50. Liu H, Li W, Gu W, Kong Y, Yang N, Chen L. Immunoregulatory effects of carvedilol on rat experimental autoimmune myocarditis. Scand J Immunol 2010; 71: 38-44.
51. Yuan Z, Kishimoto C, Shioji K, Nakamura H, Yodoi J, Sasayama S. Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression. Cardiovasc Res 2002; 55: 320-8.
52. Amin JK, Xiao L, Pimental DR, et al. Reactive oxygen species mediate a-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 2001; 33: 131-9.
53. Qin F, Rounds NK, Mao W, Kawai K, Liang CS. Antioxidant vitamins prevent cardiomyocyte apoptosis produced by norepi-nephrine infusion in ferrets. Cardiovasc Res 2001; 51: 736-48.
54. Singal PK, Beamish RE, Dhalla NS. Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Adv Exp Med Biol 1983; 161: 391-401.
55. Obata T, Yamanaka Y. Cardiac microdialysis of salicylic acid: OH generation on nonenzymatic oxidation by norepinephrine in rat heart. Biochem Pharmacol 1997; 53: 1375-8.
56. Yuan ZY, Shioji K, Kihara Y, Takenaka H, Onozawa Y, Kishimoto C. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Am J Physiol Heart Circ Physiol 2004; 286: H83-90.
57. Yuan ZY, Shioji K, Nimata M, Kishimoto C. Cardioprotective effects of carvedilol on acute autoimmune myocarditis. Mol Cell Biochem 2004; 259: 223-8.
58. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263: 92-8.
59. Feuerstein GZ, Shusterman NH, Ruffolo RR. Carvedilol update IV: Prevention of oxidative stress, cardiac remodeling and progression congestive heart failure. Drugs Today 1997; 33: 453-73.
60. Feuerstein GZ, Shusterman NH, Ruffolo RR. Comparison of me-toprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. Eur J Pharmacol 1998; 351: 341-50.
61. Magsio CH, Hamouda W, Bapna V, et al. Nadolol inhibits reactive oxygen species generation by leukocytes and linoleic acid oxidation. Am J Cardiol 2000; 86: 443-8.
62. Flesch M, Maack C, Cremers B, Bäumer AT, Südkamp M, Böhm M. Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation 1999; 100: 346-353.
63. Afanasyeva MRN. Immunemediators in inflammatory heart disease: insights from a mouse model. Eur Heart J 2002; 4: I31-6.
64. Nishio R, Sasayama S, Matsumori A. Left ventricular pressure-volume relationship in a murine model of congestive heart failure due to acute viral myocarditis. J Am Coll Cardiol 2002; 40: 1506-14.
65. Cheung C, Luo H, Yanagawa B, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in coxsackievirus-induced myocarditis. Cardiovasc Pathol 2006;15: 63-74.
66. Heymans S, Pauschinger M, De Palma A, et al. Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis.Circulation 2006; 114: 565-73.
67. Crocker SJ, Frausto RF, Whitmire JK, Benning N, Milner R, Whit-ton JL. Amelioration of coxsackievirus B3-mediated myocarditis by inhibition of tissue inhibitors of matrix metalloproteinase-1. Am J Pathol 2007; 171: 1762-73.
68. Cheung C, Marchant D, Walker EKY, et al. Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice. Circulation 2008; 117: 1574-82.
69. Westermann D, Savvatis K, Schultheiss HP, Tschöpe C. Immuno-modulation and matrix metalloproteinases in viral myocarditis. J Mol Cell Cardiol 2010; 48: 468-73.
70. Xiu-qing L, Na-dan Z, Yue-Cun L. Effect of carvedilol on expression of TNF-a, MMP-3 and TIMP-1 in mice with acute viral myocarditis. Chin J New Drugs 2011; 20: 736-39.